公开(公告)号：US20230390296A1

公开(公告)日：2023-12-07

申请号：US18250927

申请日：2021-10-29

Applicant: KEIO UNIVERSITY ,  OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC.

Inventor： Motoshi HAYANO ,  Hiroyuki KOUJI

IPC: A61K31/519 ,  A61K31/53 ,  A61K31/675 ,  A61P21/00

CPC classification number: A61K31/519 ,  A61K31/53 ,  A61K31/675 ,  A61P21/00

Abstract: The present disclosure has solved problems associated with the TGF-β family or the like, which is called Myostatin/GDF-8 as a molecular mechanism and targeted by sarcopenia, by evaluating a pharmaceutical product in physiological aging models, and in particular, by evaluating an increase in muscle mass and an increase in muscle strength; and has overcome harmful effects by applying targets of diseases different from sarcopenia such as dystrophia. The present disclosure has unexpectedly found a use for an OK-1-related compound as a sarcopenia treatment method through a pathway different from that of Wnt signal (proliferation of muscle stem cells) associated with Wnt/β-catenin inhibition, and is thus provided due to the findings.

公开(公告)号：US20220331300A1

公开(公告)日：2022-10-20

申请号：US17596101

申请日：2020-06-03

Applicant: OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC.

Inventor： Shigeru MATSUOKA ,  Akira KATOH ,  Tadashi MISHINA ,  Kentaro YAMADA ,  Atsushi YOSHIMORI ,  Toshimasa ISHIZAKI ,  Akira NISHIZONO ,  Hiroyuki KOUJI

IPC: A61K31/439 ,  A61P31/14

Abstract: The present disclosure provides compounds useful in the treatment and prevention of rabies. The present disclosure provides compounds represented by formula XXIF or XXIB [in the formulas, R1, R2A, R2B, R3, and R4 are as defined in the specification], solvates or pharmaceutically acceptable salts thereof, the use of these compounds, solvates or pharmaceutically acceptable salts thereof to treat or prevent rabies, pharmaceutical compositions including these compounds, solvates or pharmaceutically acceptable salts thereof, and a method for treating and preventing rabies using the same.